Lipid Profiles and Liver Enzymes in Autistic Patients in Iraq, a Case-Control Study
DOI:
https://doi.org/10.51699/emjms.v26i4.45Keywords:
Autism, Lipid Profile, A Liver Enzyme.Abstract
his study investigated possible differences in lipid profile and liver enzymes between autistic children and healthy controls. The study included 32 autistic patients (26 males, 6 females, 5-10 years) and 32 age- and gender-matched healthy subjects. Blood samples were taken from all participants, and cholesterol, triglycerides, HDL, LDL, VLDL, ALP, ALT, and AST levels were measured. The results showed that the levels of cholesterol, triglycerides, VLDL, ALT, and AST were significantly reduced in the autistic group compared to the control group No significant differences were observed in the levels of HDL, LDL and ALP. ROC analysis revealed strong discriminatory power for ALT and AST to discriminate between autistic and healthy children. The Pearson correlation matrix showed strong positive correlations between most of the measured parameters. These findings are consistent with previous studies suggesting altered lipid metabolism in autism. The observed reduction in lipid levels may be related to its important role in brain development and synaptogenesis. Low HDL levels may be associated with impaired lipid metabolism in autistic individuals. Significant differences in liver enzymes (ALT and AST) suggest the possibility of mitochondrial dysfunction in autistic children. This study highlights the potential role of lipid profile and liver enzyme testing in the understanding and diagnosis of autism. Further research is needed to investigate the underlying mechanisms by which these factors are associated with autism spectrum disorders.
References
Lord C, Elsabbagh M, Baird G, Veenstra-Vanderweele J. Autism spectrum disorder. The Lancet. 2018;392:508–20. DOI: https://doi.org/10.1016/S0140-6736(18)31129-2
Petrova N. Autism Spectrum Disorders in Adults. Review. Psychiatry, Psychother Clin Psychol. 2022;13:179–91.
World Health Organization. The ICD-10 classification of mental and behavioural disorders: Diagnostic criteria for research. 1993.
Cheng Y, Bololia L. The Effects of Augmented Reality on Social Skills in Children with an Autism Diagnosis: A Preliminary Systematic Review. J Autism Dev Disord. 2024;54:1317–31. DOI: https://doi.org/10.1007/s10803-022-05878-4
Ross A, Grove R, McAloon J. The relationship between camouflaging and mental health in autistic children and adolescents. Autism Res. 2023;16:190–9. DOI: https://doi.org/10.1002/aur.2859
Christensen DL, Baio J, Van Naarden Braun K, Bilder D, Charles J, Constantino JN, et al. Prevalence and characteristics of autism spectrum disorder among children aged 8 years - Autism and developmental disabilities monitoring network, 11 sites, United States, 2012. MMWR Surveill Summ. 2016;65:1–23. DOI: https://doi.org/10.15585/mmwr.ss6503a1
Maenner MJ, Warren Z, Williams AR, Amoakohene E, Bakian A V., Bilder DA, et al. Prevalence and Characteristics of Autism Spectrum Disorder Among Children Aged 8 Years — Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2020. MMWR Surveill Summ. 2023;72. DOI: https://doi.org/10.15585/mmwr.ss7202a1
Talantseva OI, Romanova RS, Shurdova EM, Dolgorukova TA, Sologub PS, Titova OS, et al. The global prevalence of autism spectrum disorder: A three-level meta-analysis. Frontiers in Psychiatry. 2023;14. DOI: https://doi.org/10.3389/fpsyt.2023.1071181
Al-Ayadhi L, Halepoto DM. Role of proteomics in the discovery of autism biomarkers. Journal of the College of Physicians and Surgeons Pakistan. 2013;23:137–43.
AR, Lane AL, Werner BA, McLees SE, Fletcher TS, Frye RE. Modern Biomarkers for Autism Spectrum Disorder: Future Directions. Mol Diagnosis Ther. 2022;26:483–95. DOI: https://doi.org/10.1007/s40291-022-00600-7
Esposito CM, Buoli M, Ciappolino V, Agostoni C, Brambilla P. The role of cholesterol and fatty acids in the etiology and diagnosis of autism spectrum disorders. International Journal of Molecular Sciences. 2021;22. DOI: https://doi.org/10.3390/ijms22073550
Petrov AM, Kasimov MR, Zefirov AL. Cholesterol in the pathogenesis of alzheimer’s, parkinson’s diseases and autism: Link to synaptic dysfunction. Acta Naturae. 2017;9:26–37. DOI: https://doi.org/10.32607/20758251-2017-9-1-26-37
Dai L, Zou L, Meng L, Qiang G, Yan M, Zhang Z. Cholesterol Metabolism in Neurodegenerative Diseases: Molecular Mechanisms and Therapeutic Targets. Molecular Neurobiology. 2021;58:2183–201. DOI: https://doi.org/10.1007/s12035-020-02232-6
Cohen BI. GABA-transaminase, the liver and infantile autism. Med Hypotheses. 2001;57:673–4. DOI: https://doi.org/10.1054/mehy.2001.1350
Filipek PA, Juranek J, Nguyen MT, Cummings C, Gargus JJ. Relative carnitine deficiency in autism. Journal of Autism and Developmental Disorders. 2004;34:615–23. DOI: https://doi.org/10.1007/s10803-004-5283-1
Karim M, Begum S, Shahzadi S. Serum Lactate, AST, ALT in Male Autistic Children in Bangladesh. J Bangladesh Soc Physiol. 2016;10:56–60. DOI: https://doi.org/10.3329/jbsp.v10i2.27165
Kalas MA, Chavez L, Leon M, Taweesedt PT, Surani S. Abnormal liver enzymes: A review for clinicians. World J Hepatol. 2021;13:1688–98. DOI: https://doi.org/10.4254/wjh.v13.i11.1688
Kim EK, Neggers YH, Shin CS, Kim E, Kim EM. Alterations in lipid profile of autistic boys: A case control study. Nutr Res. 2010;30:255–60. DOI: https://doi.org/10.1016/j.nutres.2010.04.002
Nakamura K, Sekine Y, Ouchi Y, Tsujii M, Yoshikawa E, Futatsubashi M, et al. Brain serotonin and dopamine transporter bindings in adults with high-functioning autism. Arch Gen Psychiatry. 2010;67:59–68. DOI: https://doi.org/10.1001/archgenpsychiatry.2009.137
Makris G, Chrousos G, Sabico S, Abd-Alrahman S, Al-Daghri N, Chouliaras G, et al. Serum concentrations of the endocrine disruptorsorganochlorine pesticides (OCPS) in Greek children with neurodevelopmental disorders. Horm Res Paediatr. 2018;90 Supplement 1:501–2.
El-Ansary A, Al-Ayadhi L. Lipid mediators in plasma of autism spectrum disorders. Lipids Health Dis. 2012;11. DOI: https://doi.org/10.1186/1476-511X-11-160
Grayaa S, Zerbinati C, Messedi M, HadjKacem I, Chtourou M, Ben Touhemi D, et al. Plasma oxysterol profiling in children reveals 24-hydroxycholesterol as a potential marker for Autism Spectrum Disorders. Biochimie. 2018;153 September:80–5. DOI: https://doi.org/10.1016/j.biochi.2018.04.026
Cartocci V, Servadio M, Trezza V, Pallottini V. Can cholesterol metabolism modulation affect brain function and behavior? J Cell Physiol. 2017;232:281–6. DOI: https://doi.org/10.1002/jcp.25488
Usui N, Iwata K, Miyachi T, Takagai S, Wakusawa K, Nara T, et al. VLDL-specific increases of fatty acids in autism spectrum disorder correlate with social interaction. EBioMedicine. 2020;58. DOI: https://doi.org/10.1016/j.ebiom.2020.102917
Patrick RP, Ames BN. Vitamin D hormone regulates serotonin synthesis. Part 1: Relevance for autism. FASEB Journal. 2014;28:2398–413. DOI: https://doi.org/10.1096/fj.13-246546
Kępka A, Ochocińska A, Chojnowska S, Borzym-Kluczyk M, Skorupa E, Knaś M, et al. Potential role of l-carnitine in autism spectrum disorder. J Clin Med. 2021;10:1–26. DOI: https://doi.org/10.3390/jcm10061202
Weissman JR, Kelley RI, Bauman ML, Cohen BH, Murray KF, Mitchell RL, et al. Mitochondrial disease in autism spectrum disorder patients: A cohort analysis. PLoS One. 2008;3. DOI: https://doi.org/10.1371/journal.pone.0003815
Marin-Garcia J, Ananthakrishnan R, Goldenthal MJ, Filiano JJ, Sarnat HB. Skeletal muscle mitochondrial defects in nonspecific neurologic disorders. Pediatr Neurol. 1999;21:538–42. DOI: https://doi.org/10.1016/S0887-8994(99)00038-7
Nickel K, Menke M, Endres D, Runge K, Tucci S, Schumann A, et al. Altered markers of mitochondrial function in adults with autism spectrum disorder. Autism Res. 2023;16:2125–38. DOI: https://doi.org/10.1002/aur.3029
Chinnery PF, Turnbull DM. Mitochondrial medicine. QJM Mon J Assoc Physicians. 1997;90:657–67. DOI: https://doi.org/10.1093/qjmed/90.11.657
Turner M. The role of drugs in the treatment of autism. Aust Prescr. 2020;43:185–90. DOI: https://doi.org/10.18773/austprescr.2020.054
Cojocaru M, Cojocaru IM, Silosi I, Vrabie CD. Gastrointestinal manifestations in systemic autoimmune diseases. Maedica (Buchar). 2011;6:45–51.
Stolar O, Hazan A, Vissoker RE, Kishk IA, Barchel D, Lezinger M, et al. Medical cannabis for the treatment of comorbid symptoms in children with autism spectrum disorder: An interim analysis of biochemical safety. Front Pharmacol. 2022;13. DOI: https://doi.org/10.3389/fphar.2022.977484
